JP2022501341A5 - - Google Patents

Info

Publication number
JP2022501341A5
JP2022501341A5 JP2021514531A JP2021514531A JP2022501341A5 JP 2022501341 A5 JP2022501341 A5 JP 2022501341A5 JP 2021514531 A JP2021514531 A JP 2021514531A JP 2021514531 A JP2021514531 A JP 2021514531A JP 2022501341 A5 JP2022501341 A5 JP 2022501341A5
Authority
JP
Japan
Application number
JP2021514531A
Other languages
Japanese (ja)
Other versions
JP2022501341A (ja
JPWO2020061007A5 (https=
JP7546552B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051457 external-priority patent/WO2020061007A1/en
Publication of JP2022501341A publication Critical patent/JP2022501341A/ja
Publication of JP2022501341A5 publication Critical patent/JP2022501341A5/ja
Publication of JPWO2020061007A5 publication Critical patent/JPWO2020061007A5/ja
Application granted granted Critical
Publication of JP7546552B2 publication Critical patent/JP7546552B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514531A 2018-09-17 2019-09-17 ポリマーベースの高分子プロドラッグ Active JP7546552B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732199P 2018-09-17 2018-09-17
US62/732,199 2018-09-17
PCT/US2019/051457 WO2020061007A1 (en) 2018-09-17 2019-09-17 Polymer-based macromolecular prodrugs

Publications (4)

Publication Number Publication Date
JP2022501341A JP2022501341A (ja) 2022-01-06
JP2022501341A5 true JP2022501341A5 (https=) 2022-09-26
JPWO2020061007A5 JPWO2020061007A5 (https=) 2022-09-26
JP7546552B2 JP7546552B2 (ja) 2024-09-06

Family

ID=69887739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514531A Active JP7546552B2 (ja) 2018-09-17 2019-09-17 ポリマーベースの高分子プロドラッグ

Country Status (10)

Country Link
US (4) US11253603B2 (https=)
EP (1) EP3852793B1 (https=)
JP (1) JP7546552B2 (https=)
KR (1) KR20210072002A (https=)
CN (2) CN119950749A (https=)
AU (1) AU2019344783B2 (https=)
CA (1) CA3112778A1 (https=)
EA (1) EA202190799A1 (https=)
MX (1) MX2021003116A (https=)
WO (1) WO2020061007A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7546552B2 (ja) * 2018-09-17 2024-09-06 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ポリマーベースの高分子プロドラッグ
CN115443947B (zh) * 2022-10-12 2023-11-21 江苏省人民医院(南京医科大学第一附属医院) 高血压动物模型的制备方法
WO2025101904A1 (en) * 2023-11-08 2025-05-15 The Children's Hospital Of Philadelphia Norepinephrine transporter-targeted prodrugs for cancer therapy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052861A1 (de) * 1998-04-09 1999-10-21 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Neue benzylguanidinderivate für die therapie, in-vivo- und in-vitro-diagnostik
JP2002255821A (ja) * 2001-03-06 2002-09-11 Yakult Honsha Co Ltd 抗癌剤耐性癌に対する治療剤
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20040258754A1 (en) * 2003-06-18 2004-12-23 Valery Alakhov Compositions for oral administration of camptothecin and its analogs
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
BRPI0415858A (pt) * 2003-10-29 2007-01-09 Sonus Pharma Inc compostos de medicamentos terapêuticos modificados por tocoferol
WO2007106549A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for treating brain cancer
JP2010503706A (ja) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド リジン系ポリマーリンカー
US20090074074A1 (en) 2007-06-29 2009-03-19 The Hong Kong University Of Science And Technology Multiple description encoder and decoder for transmitting multiple descriptions
KR101671537B1 (ko) * 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
HUE047352T2 (hu) 2008-09-23 2020-04-28 Nektar Therapeutics Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)
CA2738807A1 (en) 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN101385860B (zh) * 2008-10-31 2011-11-02 美国草药泉有限责任公司 喜树碱及其衍生物的非线性聚乙二醇前药
US20120171201A1 (en) 2009-07-22 2012-07-05 Enzon Pharmaceuticals, Inc. Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
ME03396B (me) 2009-11-18 2020-01-20 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
CN102626518B (zh) * 2012-05-09 2014-05-28 中国药科大学 一种包载难溶性药物的泊洛沙姆/两亲性多糖混合胶束的制备和应用
CN104813167B (zh) 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
US9863949B2 (en) 2013-05-31 2018-01-09 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents
DK3052101T3 (da) * 2013-10-04 2019-12-16 Prolynx Llc Konjugater af sn-38 med langsom frigivelse
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016050210A1 (zh) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物及其制备方法
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药(苏州)股份有限公司 多臂的聚合靶向抗癌偶联物
US20200163956A1 (en) 2016-09-06 2020-05-28 Cerebral Therapeutics LLC Direct brain administration of chemotherapeutics to the csf for patients with primary and secondary brain tumors
EP3613792B1 (en) 2017-04-21 2021-02-24 Bright Gene Bio-Medical Technology Co., Ltd. Multi-arm targeted anti-cancer conjugate
JP7381083B2 (ja) 2017-09-08 2023-11-15 フォスプラティン テラピューティクス インコーポレイテッド 免疫調節剤としてのホスファプラチン化合物およびその治療的使用
WO2019090141A1 (en) 2017-11-02 2019-05-09 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP7546552B2 (ja) * 2018-09-17 2024-09-06 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ポリマーベースの高分子プロドラッグ
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021016821A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)